KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Accumulated Depreciation & Amortization (2016 - 2025)

Vertex Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 17 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $1.2 billion for Q4 2025, up 13.08% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (up 13.08% YoY), and the annual figure for FY2025 was $1.2 billion, up 13.08%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $1.2 billion at Vertex Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for VRTX hit a ceiling of $1.2 billion in Q4 2025 and a floor of $896.0 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $1.1 billion (2024), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 15.73% in 2023 and later decreased 10.44% in 2024.
  • Vertex Pharmaceuticals' Accumulated Depreciation & Amortization stood at $896.0 million in 2021, then rose by 14.65% to $1.0 billion in 2022, then increased by 15.73% to $1.2 billion in 2023, then decreased by 10.44% to $1.1 billion in 2024, then rose by 13.08% to $1.2 billion in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $1.2 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.2 billion (Q4 2023) per Business Quant data.